Dendritic Cell Cancer Vaccines Market to Grow at Highest Value by 2026

Global Dendritic Cell Cancer Vaccines Market by Product Type (CreaVax, Sipuleucel-T (Provenge), and Others) and by End Users (Pediatrics and Adults) - Opportunities and Forecasts, 2019-2026

Global Dendritic Cell Cancer Vaccines Market Key Segmentation:

By Product Type

• CreaVax
• Sipuleucel-T (Provenge)
• Others

By End User

• Pediatrics
• Adults

Global Dendritic Cell Cancer Vaccines Market Outlook 2019-2026:

Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals. Increase in prevalence of cancer, improvement of technology such as drug innovations regarding cancer, upsurge in awareness about cancer and their available therapies in the market, and increase in health care expenditure drive the market. In contrast, low accessibility to vaccines in remote areas and stringent regulatory procedures restrain the market.

The key players of the dendritic cell cancer vaccine market are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation), Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.

This report segments the global dendritic cell cancer vaccine market based on type, end user, and region. Based on type, it is categorized into CreaVax, Sipuleucel-T (Provenge), and others. Based on end user, it is classified into pediatrics, and adults. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.